| P2093 | author name string | John J. Alam | |
| P2860 | cites work | Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury | Q24530090 |
| | The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity | Q27625099 |
| | Mechanisms of caspase activation and inhibition during apoptosis | Q27919623 |
| | Proliferation, cell cycle and apoptosis in cancer | Q28189476 |
| | Genasense | Q29005899 |
| | The biochemistry of apoptosis | Q29547741 |
| | Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 |
| | Induction of apoptosis by cancer chemotherapy. | Q33876771 |
| | Apoptosis after experimental stroke: fact or fashion? | Q34076430 |
| | Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades | Q34086191 |
| | Programmed cell death in cerebral ischemia | Q34140005 |
| | Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 |
| | Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation | Q34381861 |
| | Apoptosis in myocardial infarction | Q35043424 |
| | Nature's TRAIL--on a path to cancer immunotherapy | Q35046572 |
| | Apoptosis in Huntington's disease. | Q35092246 |
| | Apoptosis and brain ischaemia | Q35092250 |
| | Prospects for antiapoptotic drug therapy of neurodegenerative diseases | Q35092261 |
| | Apoptosis and caspases in neurodegenerative diseases | Q35097801 |
| | Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists | Q35124562 |
| | Apoptosis after traumatic human spinal cord injury | Q36899539 |
| | Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury | Q37250532 |
| | A novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin reduces myocardial ischemic injury | Q40687709 |
| | Differential requirement for caspase 9 in apoptotic pathways in vivo. | Q41015558 |
| | Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis | Q43559207 |
| | Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis. | Q43699287 |
| | Caspase-dependent and serine protease-dependent DNA fragmentation of myocytes in the ischemia-reperfused rabbit heart: these inhibitors do not reduce infarct size | Q43772704 |
| | Therapeutic strategies targeting caspase inhibition following spinal cord injury in rats | Q44214588 |
| | The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury | Q44347302 |
| | Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte | Q45018156 |
| | In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia | Q47232133 |
| | Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rat heart | Q47243708 |
| | MRI of acute cerebral infarcts, increased contrast enhancement with continuous infusion of gadolinium | Q48200439 |
| | Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. | Q48236502 |
| | Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation | Q48373661 |
| | Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor | Q57424632 |
| | Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure | Q58314378 |
| | Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation | Q70607132 |
| | In vivo detection of cell death in the area at risk in acute myocardial infarction | Q73088051 |
| | Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis | Q73700066 |
| | Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival | Q73928271 |
| | Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury | Q74154142 |
| | Visualisation of cell death in vivo in patients with acute myocardial infarction | Q74236895 |
| | Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure | Q74300335 |
| | The variable morphological coexistence of apoptosis and necrosis in human myocardial infarction: significance for understanding its pathogenesis, clinical course, diagnosis and prognosis | Q77117126 |
| | Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury | Q78060140 |
| | Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo | Q78202589 |
| | Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome | Q78602259 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biotechnology | Q7108 |
| | bioengineering | Q580689 |
| P304 | page(s) | 479-483 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Trends in Biotechnology | Q2451465 |
| P1476 | title | Apoptosis: target for novel drugs | |
| P478 | volume | 21 | |